New Mexico is currently home to 415 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Albuquerque, Santa Fe, Las Cruces and Farmington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Amplitude Titration to Improve ECT Clinical Outcomes
NCT05699226
Recruiting
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
12/15/2023
Locations: University of New Mexico Health Science Center, Albuquerque, New Mexico
Conditions: Depression, ECT, Cognitive Change
Register for Updates
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
NCT05020535
Recruiting
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Intracerebral Hemorrhage
Register for Updates
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
NCT04223856
Recruiting
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Urothelial Cancer
Register for Updates
Emergency Department-Initiated Buprenorphine Validation Network Trial
NCT04225598
Recruiting
This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). Once implementation is adequately achieved, the sites will (2) conduct a randomized controlled trial (RCT) to compare the effectiveness of sublingual buprenorphi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Presybterian Hospital, Albuquerque, NM, Albuquerque, New Mexico
Conditions: Opioid-use Disorder
Register for Updates
Access to Kidney Transplantation in Minority Populations
NCT04615819
Recruiting
Hispanic/Latino (HL) and American Indian (AI) patients are more likely than whites to have kidney failure, but less likely to complete transplant evaluation or receive a kidney transplant (KT), the best treatment for kidney failure. Using comparative effectiveness research methods, we will conduct a pragmatic randomized trial to compare the efficacy and cost- effectiveness of two approaches to help HL and AI patients overcome barriers to completing transplant evaluation and receiving a KT: a str... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Kidney Diseases
Register for Updates
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies
NCT05123482
Recruiting
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: Research Site, Albuquerque, New Mexico
Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma
Register for Updates
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
NCT02922764
Recruiting
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab, docetaxel, or pembrolizumab plus carboplatin/pemetrexed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Quantum Santa Fe, Santa Fe, New Mexico
Conditions: Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Register for Updates
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT05568472
Recruiting
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Register for Updates
ALM-488 for Intra-Operative Visualization of Nerves in Head and Neck Surgery
NCT05377554
Recruiting
This protocol describes prospective, open-label, blinded, randomized controlled, multicenter pivotal studies to evaluate ALM-488.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/08/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Surgery
Register for Updates
Cycled Phototherapy
NCT03927833
Recruiting
Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (< 750 g BW or <27 weeks GA).
Gender:
All
Ages:
Between 22 weeks and 27 weeks
Trial Updated:
11/07/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Hyper Bilirubinemia, Premature Infant
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
All
Ages:
14 days and below
Trial Updated:
11/07/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
All
Ages:
Between 18 months and 26 months
Trial Updated:
11/07/2023
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates